{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:52:21Z","timestamp":1793105541449,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.rmed.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T02:36:50Z","timestamp":1519007810000},"page":"S7-S13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"S","title":["Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis"],"prefix":"10.1016","volume":"138","author":[{"given":"Milou C.","family":"Schimmelpennink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane D.M.","family":"Vorselaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frouke T.","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen A.","family":"Crommelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H.M.","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth G.M.","family":"Keijsers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2018.02.009_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1034\/j.1399-3003.1999.14d02.x","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American thoracic society. European respiratory society. World association for sarcoidosis and other granulomatous disorders","volume":"14","author":"Costabel","year":"1999","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2018.02.009_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1164\/arrd.1973.107.4.609","article-title":"A controlled trial of prednisone treatment of sarcoidosis","volume":"107","author":"Israel","year":"1973","journal-title":"Am. Rev. Respir. Dis."},{"issue":"7515","key":"10.1016\/j.rmed.2018.02.009_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(67)90493-X","article-title":"Treatment of sarcoidosis. Report of a controlled therapeutic trial","volume":"2","author":"James","year":"1967","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rmed.2018.02.009_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1378\/chest.121.1.24","article-title":"Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function","volume":"121","author":"Pietinalho","year":"2002","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2018.02.009_bib5","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"6 Pt 1","key":"10.1016\/j.rmed.2018.02.009_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/ajrccm\/142.6_Pt_1.1268","article-title":"The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis","volume":"142","author":"Baughman","year":"1990","journal-title":"Am. Rev. Respir. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2018.02.009_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.rmed.2018.02.009_bib8","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","author":"Hamzeh","year":"2014","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.02.009_bib9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.rmed.2018.02.009_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"Baughman","year":"2015","journal-title":"Lancet. Respir. Med."},{"issue":"3","key":"10.1016\/j.rmed.2018.02.009_bib11","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"7","key":"10.1016\/j.rmed.2018.02.009_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2018.02.009_bib13","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"6","key":"10.1016\/j.rmed.2018.02.009_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2018.02.009_bib15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.rmed.2018.02.009_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients","volume":"47","author":"Jamilloux","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.rmed.2018.02.009_bib17","volume":"1","author":"van Rijswijk","year":"2013"},{"issue":"1","key":"10.1016\/j.rmed.2018.02.009_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.02.009_bib19","series-title":"European Medicines Agency. Guideline on Similar Biological Medicinal Products","year":"2014"},{"issue":"10","key":"10.1016\/j.rmed.2018.02.009_bib20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2018.02.009_bib21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.04.068","article-title":"The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis","volume":"75","author":"Dapavo","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.rmed.2018.02.009_bib22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2018.02.009_bib23","first-page":"690","article-title":"Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme","volume":"11","author":"Razanskaite","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"11","key":"10.1016\/j.rmed.2018.02.009_bib24","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.rmed.2018.02.009_bib25","series-title":"Position Paper: Behandeling Van Sarco\u00efdose Met TNF-Alfa Blokkerende Middelen","author":"Drent","year":"2012"},{"key":"10.1016\/j.rmed.2018.02.009_bib26","series-title":"Postition Paper: Vergelijkbaarheid en plaatsbepaling biosimilars van de TNF-alfa blokker Remicade","author":"Veltkamp","year":"2015"},{"issue":"2","key":"10.1016\/j.rmed.2018.02.009_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.rmed.2018.02.009_bib28","series-title":"SF-36 Health Survey Manual and Interpretation Guide","author":"Ware","year":"1993"},{"issue":"1","key":"10.1016\/j.rmed.2018.02.009_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.rmed.2018.02.009_bib30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","article-title":"Pain: a review of three commonly used pain rating scales","volume":"14","author":"Williamson","year":"2005","journal-title":"J. Clin. Nurs."},{"issue":"2","key":"10.1016\/j.rmed.2018.02.009_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-199915020-00003","article-title":"Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II","volume":"15","author":"Samsa","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.rmed.2018.02.009_bib32","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.rmed.2018.02.009_bib33","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2018.02.009_bib34","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.rmed.2006.06.025","article-title":"ACE I\/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis","volume":"101","author":"Kruit","year":"2007","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2018.02.009_bib35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00259-009-1097-x","article-title":"18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis","volume":"36","author":"Keijsers","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.rmed.2018.02.009_bib36","first-page":"123","article-title":"18F-FDG PET as a predictor of pulmonary function in sarcoidosis","volume":"28","author":"Keijsers","year":"2011","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"2","key":"10.1016\/j.rmed.2018.02.009_bib37","first-page":"143","article-title":"18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab","volume":"25","author":"Keijsers","year":"2008","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"5","key":"10.1016\/j.rmed.2018.02.009_bib38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MCP.0000000000000401","article-title":"Many faces of neurosarcoidosis: from chronic meningitis to myelopathy","volume":"23","author":"Fritz","year":"2017","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmed.2018.02.009_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0981-6","article-title":"A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.rmed.2018.02.009_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.rmed.2018.02.009_bib41","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14712598.2017.1238454","article-title":"The design of clinical trials to support the switching and alternation of biosimilars","volume":"16","author":"Faccin","year":"2016","journal-title":"Expert Opin Biol Ther."},{"issue":"10086","key":"10.1016\/j.rmed.2018.02.009_bib42","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118300386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118300386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:38:08Z","timestamp":1760614688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611118300386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":42,"alternative-id":["S0954611118300386"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.02.009","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of infliximab biosimilar Inflectra\u00ae in severe sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}